An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors CSL Behring
- 02 Oct 2017 Planned End Date changed from 1 Jan 2018 to 19 Jan 2018.
- 02 Oct 2017 Planned primary completion date changed from 1 Jan 2018 to 12 Jan 2018.
- 07 Feb 2017 Status changed from not yet recruiting to recruiting.